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Abstract 
Background: Biomarkers play a pivotal role in the diagnosis and management of patients with acute coronary syn‑
drome. This study aimed to investigate the differences in level of several biomarkers, i.e. C‑reactive protein, myelop‑
eroxidase, soluble CD40 ligand and placental growth factor, between acute coronary syndrome and chronic stable 
angina patients. The relationship between these biomarkers in the coronary circulation and systemic circulation was 
also investigated.
Methods: A total of 79 patients were recruited in this study. The coronary blood was sampled from occluded coro‑
nary artery, while the peripheral venous blood was withdrawn from antecubital fossa. The serum concentrations of 
C‑reactive protein, soluble CD40 ligand and placental growth factor and plasma concentration of myeloperoxidase 
were measured using ELISA method.
Results: The systemic level of the markers measured in the peripheral venous blood was significantly increased in 
acute coronary syndrome compared to chronic stable angina patients. The concentrations of the C‑reactive protein, 
myeloperoxidase and soluble CD40 ligand taken from peripheral vein were closely similar to the concentration found 
in coronary blood of ACS patients. The level of placental growth factor was significantly higher in coronary circulation 
than its systemic level.
Conclusion: The concentration of these C‑reactive protein, myeloperoxidase, soluble CD40 ligand and placental 
growth factor were significantly increased in acute coronary syndrome patients. The concentration of the markers 
measured in the systemic circulation directly reflected those in the local coronary circulation. Thus, these markers 
have potential to become a useful tool in predicting plaque vulnerability in the future.
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Background
Acute coronary syndrome (ACS) refers to a spectrum 
of clinical manifestations, which includes disruption of 
coronary plaque, thrombosis, embolization and varying 
degrees of perfusion obstruction. The understanding of 
the events in pathophysiology of ACS contributes to the 
emergence of several biomarkers such as myeloperoxi-
dase (MPO), soluble CD40 ligand (sCD40L) and placen-
tal growth factor (PlGF).
Myeloperoxidase is released from neutrophilic gran-
ules and monocytes during inflammation [1]. It plays a 
pivotal role in plaque instability by causing fibrous cap 
disintegration. It catalyzes the formation of hypochlorite 
from chloride and hydrogen peroxide. Its end product 
hypochlorous acid, HOCl, activates matrix metallopro-
teinases (MMPs) [2] and deactivates inhibitors of MMPs 
[3]. Thus, it promotes weakening of the fibrous cap and 
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results in the formation of vulnerable atherosclerotic 
plaque. Besides MPO, the platelet-derived sCD40L also 
plays an essential role in plaque destabilization. It stimu-
lates vascular endothelial cells inflammation by the secre-
tion of chemokines and cytokines [4]. Membrane bound 
CD40L and sCD40L interact with the CD40 receptor 
molecule on B cells, monocytes, macrophages, endothe-
lial and smooth muscle cells in atheroma. This leads to 
the release of MMPs which subsequently destabilize the 
plaque [5]. The PlGF is a platelet-derived protein that 
has a high homology and functions similar to vascular 
endothelial growth factor. It involves in the regulation of 
vascular endothelial growth by recruiting monocytes [6]. 
Moreover, PlGF might form a heterodimer with vascular 
endothelial growth factor, thereby enhancing pro-ath-
erogenic effects of this growth factor by either reducing 
the bioavailability of vascular endothelial growth factor 
(VEGF) or, at the other extreme, by increasing the activ-
ity of low concentrations of VEGF [7].
There were studies reporting on the elevated expression 
of MPO, sCD40L and PlGF in ACS patients [8–10]. Most 
of these studies measured the concentration of markers 
in the systemic circulation. The researchers generally 
presumed that the elevation of markers sampled from 
the peripheral circulation is a reflection of the release of 
these markers from the ruptured coronary plaque. How-
ever, there is a possibility that the markers are released 
from non-coronary sources, which subsequently trans-
form the stable plaque into unstable form. Therefore, this 
study aimed to measure the systemic and coronary levels 
of MPO, sCD40L, PlGF together with C-reactive protein 
(CRP), in patients with ACS who underwent a coronary 
angiogram and/or percutaneous intervention as clini-
cally indicated compared to chronic stable angina (CSA) 
patients scheduled for elective angioplasty.
Methods
Participants
The ethical approval was obtained from Human 
Research Ethics Committee of Universiti Sains Malay-
sia and National Heart Institute, Malaysia prior to study 
implementation. All participants agreed to participate 
and signed the written informed consent. A total of 
39 patients with ACS and 40 patients with CSA were 
recruited. The ACS cases included ST elevation myo-
cardial infarction (STEMI), non ST elevation myocardial 
infarction (NSTEMI) and unstable angina (UA). Patients 
are defined as STEMI when they present with biomark-
ers of myocardial necrosis (i.e. typical rise and gradual 
fall of troponin or more rapid rise and fall of creatine 
kinase MB) and at least one of the following criteria: 
clinical history of ischemic type chest pain; development 
of pathologic Q waves on the electrocardiogram (ECG); 
ECG changes indicative of ischemia. Patients are defined 
as UA/NSTEMI when they present with three possible 
types of chest pain [i.e. new onset (2 months) angina that 
is severe and/or frequent (>3 episodes per day), accel-
erating angina and/or angina at rest] with ECG changes 
(ST segment depression >0.05  mV or T-wave inversion 
>0.2  mV in the precordial leads). NSTEMI is differenti-
ated from UA by the presence of elevated serum cardiac 
markers. All ACS patients underwent a coronary angio-
gram within 7  days after admission, and an angiogram 
was routinely scheduled for CSA patients.
Blood sampling and processing
The blood sample was collected from ACS patient within 
48 h after onset of symptom. The coronary blood sample 
was drawn from the culprit artery for ACS patients and the 
most severely stenotic artery for CSA patients. On the iden-
tification of the lesion, 100 IU/kg heparin was administered 
intravenously during the procedure. In ACS patients, the 
culprit coronary artery was engaged with guiding catheter 
and subsequently wired with guide wire. An export aspira-
tion catheter was advanced a few centimeters distal to the 
culprit lesion after crossing the culprit lesion. Aspiration of 
10 mL of intracoronary blood was done with a syringe from 
the distal end of the lesion ensued. Patients were excluded 
from the study if the aspiration catheter failed to pass the 
culprit lesion for any reason. In CSA patients, intracoro-
nary blood was drawn from the coronary artery at the time 
of guiding catheter engagement into the coronary ostium 
of the most severe stenotic artery. Balloon angioplasty 
and stent implantation were then performed according to 
standard techniques. Another 10 mL of whole blood sam-
ple was drawn from a peripheral vein (antecubital fossa) 
after the angioplasty procedure. The blood samples were 
collected in both plain tube and EDTA tube in order to 
obtain serum and plasma samples after centrifugation. The 
samples were then stored at −80 °C until further analysis.
Measurement of MPO, sCD40L, PlGF and CRP
Serum sCD40L and PlGF levels were measured using com-
mercially available enzyme-linked immunosorbent assay 
kits (R&D Systems, Abingdon, UK). Serum CRP level was 
assessed using a commercial ELISA kit from DRG diag-
nostics (DRG International, USA). Quantitative measure-
ment of MPO in plasma was performed using optimized 
in-house ELISA method adopted from a previous study 
[11]. In general, ELISA was run with plates pre-coated 
with antibodies. Standards, samples, and a conjugated 
detection antibody were added to each well. A horserad-
ish peroxidase/3,3′,5,5′-tetramethylbenzidine-system was 
used for the enzymatic color reaction. Plates were read at 
450  nm on ELISA reader (Thermo Scientific, USA). Pro-
tein concentrations were calculated by comparing optical 
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density (OD) values of samples with OD of known con-
centrations of the standards prepared by the kit’s manufac-
turer. The intra-assay CVs (CRP 3.0 %, MPO 1.6 %, sCD40L 
2.9 %, PlGF 2.4 %) and inter-assay CVs (CRP 6.1 %, MPO 
5.0 %, sCD40L 6.2 %, PlGF 11.2 %) were calculated.
Statistical analysis
Statistical analysis was performed using SPSS software ver-
sion 18 (SPSS Inc., Chicago, IL, USA). Data were presented 
as mean ± SD However, if the data were not normally dis-
tributed the median and inter-quartile range were used. 
Data normality was verified using the Shapiro–Wilks test. 
Independent T-tests (parametric) or Mann–Whitney U test 
(non-parametric) was used to study the difference between 
groups (ACS vs. CSA) and sampling sites (coronary vs. 
systemic). Categorical data were compared using the Chi 
square test and fisher’s exact test. A p value < 0.05 was con-
sidered statistically significant. The association between 
the marker’s level and the incidence of ACS was investi-
gated using multivariate logistic regression to calculate the 
adjusted odds ratio with 95 % confidence interval (CI).
Results
Baseline characteristics of participants
Table  1 presents baseline clinical characteristics of 
patients in this study. Twenty-two ACS patients suffered 
from multiple-vessel disease instead of a single vessel 
disease. The prevalence of diabetes mellitus, hyperlipi-
daemia, smoking, and statin use were similar in both 
study groups. There was no significant difference in age 
and gender between groups. However, there were sig-
nificantly more CSA patients suffered from myocardial 
infarction previously compared to ACS patients.
Systemic levels of CRP, MPO, PlGF and sCD40L
Systemic venous levels of CRP, MPO, PlGF and sCD40L 
in both CSA and ACS groups are shown in Table 2. Con-
centrations of the four markers showed significant differ-
ences between CSA and ACS patients. The CRP, MPO, 
PlGF and sCD40L were found associated with ACS inde-
pendently, after adjusted for variables which are known 
to have an effect on marker levels (i.e. age, gender, smok-
ing and statin use) (Table 3).
Comparison between systemic and coronary markers 
levels
In patients with ACS, there was no significant differ-
ence between systemic and coronary blood levels of CRP, 
MPO and sCD40L. However, the level of PlGF in coro-
nary circulation was significantly higher than its level in 
systemic circulation (Table 4). The coronary levels of all 
markers established significant positive correlations with 
their levels in systemic circulation (Table 4).
Correlation between coronary markers levels
We did correlation test to study the coronary relationship 
between CRP, MPO, sCD40L and PlGF in ACS patients. 
The correlation between coronary levels of CRP and MPO 
did not demonstrate statistical significance (Spearman’s 
ρ = 0.208, p = 0.203). Furthermore, there was no significant 
positive correlation between coronary CRP with coronary 
sCD40L (Spearman’s ρ = 0.121, p = 0.463) and intracoro-
nary PlGF (Spearman’s ρ = 0.055, p = 0.739), as well.
Discussion
This study demonstrated that the systemic levels of CRP, 
MPO, sCD40L and PlGF were significantly higher in ACS 
compared to CSA patients. The role of inflammation in 
the pathogenesis of myocardial infarction has been tar-
geted in many studies. Numerous investigations have 
indicated CRP as a risk marker for the prediction of risk 
for future cardiovascular events [12, 13]. The association 
of CRP with cardiovascular disease is often related to 
inflammation. CRP is produced entirely by hepatocytes 
during the acute inflammatory response. However, sev-
eral studies have also suggested that atherosclerotic tis-
sue itself can release CRP [14].
Platelets are a source of inflammatory mediators [15]. 
The activation of platelets following inflammation is a 
critical component of atherothrombosis process [16]. 
The lymphocytes actively release sCD40L after plate-
let stimulation [17, 18], which eventually stimulate vas-
cular endothelial cells inflammation by the secretion of 
chemokines and cytokines [4].
Myocardial cell damage is not only related to platelet 
activation and inflammation, but it is also preceded by 
the recruitment and activation of polymorphonuclear 
neutrophils. The polymorphonuclear neutrophils release 
MPO into circulation, resulting in higher MPO level in 
ACS patients [19, 20]. Myeloperoxidase promotes plaque 
fibrous cap weakening by activating MMPs [2] and deac-
tivating MMPs inhibitors [3].
C-reactive protein, MPO, PlGF and sCD40L are not 
solely produced from human coronary plaque. They can 
be released systemically from other sources such as liver 
(CRP), circulating neutrophils (MPO), endothelial cells 
(PlGF) or circulating platelets (sCD40L). Therefore, the 
elevated markers in ACS patients could be caused by the 
substantial release from ruptured coronary plaques or pro-
duced by the occluded coronary arteries. Besides, there is a 
possibility that the markers are released systemically from 
stimulated non-coronary source, reach the coronary plaque 
site through blood circulation and trigger plaque rupture. 
In order to investigate the possible site of origin of the 
markers responsible in the pathogenesis of ACS, both local 
intracoronary and systemic concentrations of markers were 
measured, which was the primary aim of this study.
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This study showed no significant difference between 
levels of CRP, MPO and sCD40L in the coronary circu-
lation compared to systemic venous blood, in the ACS 
patients. Therefore, we speculate that the markers are 
mainly released from the non-coronary site. The non-
coronary source is possibly triggered by a specific precur-
sor prior to the release of the marker, which eventually 
contribute to the plaque rupture in ACS patients. How-
ever, since the time to sample collection after onset of 
symptom in ACS patients was quite long and up to 48 h, 
these biomarkers could be carried from coronary local 
lesion to the systemic circulation, especially if the mark-
ers were produced at an early stage of symptom. Hence, 
future study targeting blood sampling at multiple time 
intervals after onset of symptom in ACS patients should 
carried out to answer this hypothesis.
In contrast, the level of PlGF in the coronary circula-
tion was significantly higher than its level in the systemic 
Table 1 Baseline clinical characteristics of the study groups
Statistic data were given as median (IQR), mean ± SD or n, %
IQR interquartile range, SD standard deviation
* Significant with p < 0.05










53 (43–64) 46 (42–61) 0.806
Multiple vessel disease (n, %) 22 (56.4 %) 30 (75.0 %) 0.082
Hypertension (n, %) 23 (59.0 %) 32 (80.0 %) 0.042*
Diabetes mellitus (n, %) 17 (43.6 %) 22 (55.0 %) 0.311
Hyperlipidaemia (n, %) 26 (66.7 %) 27 (67.5 %) 0.937
Cholesterol (mmol/L)
median (IQR)
4.8 (1.0) 4.7 (1.1) 0.562
LDL cholesterol (mmol/L) 2.6 (2.1–3.6) 2.7 (1.9–3.4) 0.456
Triglycerides (mmol/L)
median (IQR)
1.4 (1.1–2.3) 1.8 (1.7–2.5) 0.006*
Platelet count
(×109/L) (mean ± SD)
231.0 ± 60.1 250.0 ± 58.6 0.177
Creatinine (µmol/L)
median (IQR)
107 (99–119) 99 (84–106) 0.023*
Statin (n, %) 26 (66.7 %) 27 (67.5 %) 0.937
Smoking (n, %) 14 (35.9 %) 16 (40.0 %) 0.707
Previous myocardial infarction (n, %) 2 (5.1 %) 14 (35.0 %) 0.001*
Table 2 Systemic levels of CRP, MPO, sCD40L and PlGF in both CSA and ACS patients
Data were given as median (IQR)
CRP C-reactive protein, MPO myeloperoxidase, sCD40L soluble CD40 ligand, PlGF placental growth factor
* Significant with p < 0.05, tested by Mann–Whitney U test
CRP (mg/L) MPO (ng/mL) sCD40L (ng/mL) PlGF (pg/mL)
ACS 22.03 (4.72–45.86) 529.53 (323.91–1015.33) 2.95 (1.31–7.14) 42.36 (23.72–59.64)
CSA 3.97 (2.39–8.38) 426.06 (351.28–511.93) 1.84 (0.90–3.15) 16.28 (6.63–36.44)
p value <0.001* 0.023* 0.038* <0.001*
Table 3 List of  markers and  their associations with  the 
incidence of  ACS analyzed using multivariate logistic 
regression
* Significant at p value < 0.05






CRP (mg/L) 0.102 1.107  (1.038–1.181) 0.002*
sCD40L (ng/mL) 0.195 1.216 (1.037–1.425) 0.016*
PlGF (pg/mL) 0.023 1.023 (1.006–1.041) 0.009*
MPO (ng/mL) 0.001 1.001 (1.000–1.003) 0.039*
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circulation of ACS patients. Hence, this finding predicted its 
elevation in ACS patients could be caused by the substantial 
release from ruptured coronary plaques or produced by the 
occluded coronary arteries, rather than by non-cardiac ori-
gin source. This finding and speculation were further sup-
ported by a study conducted by Iwama et al. [21]. This study 
indicated that vascular tissue, especially the endothelium 
within the infarct myocardium can substantially produce 
PlGF during acute myocardial infarction.
C-reactive protein has been detected in human coro-
nary plaques [22, 23]. The generation of CRP and its com-
plement has been reported in atherosclerotic plaque tissue 
[24], particularly the unstable plaque showed increased 
expression of CRP protein [25]. Indeed, human coronary 
artery smooth muscle cells can produce CRP in response 
to cytokines [14]. Since there was no increased CRP level 
in the coronary circulation, we hypothesized the increased 
production of CRP from systemic hepatic cells resulted 
in the markedly elevation of CRP in ACS patients. The 
result showed there was a significant decrease in coronary 
CRP in CSA patients. We may attribute the decrease to 
local uptake and catabolism of the protein by phagocytes 
in coronary plaque site. This speculation is supported by 
immunohistochemistry studies that showed the thrombi 
at culprit site contained phagocytic white blood cells with 
the presence of CRP [26].
Numerous studies have demonstrated higher concen-
tration of protein markers in the systemic blood of ACS 
patients compared to CSA. However, the comparisons 
between marker concentrations in coronary circulation 
at the site of lesion with systemic circulation were merely 
studied. The present study used a particular method to 
sample blood from coronary arteries. Coronary blood 
was collected from the coronary circulation at the site 
of the culprit lesion, where the level of those markers is 
expected to be the highest if they are released from the 
ruptured atherosclerotic plaque.
Coronary CRP levels demonstrated a non significant 
positive correlation with coronary MPO, sCD40L and PlGF 
levels. The weak correlations suggested the markers reflect 
distinct signal pathways other than systemic inflammation 
that eventually contribute to a pro-inflammatory and pro-
coagulating environment in the coronary circulation.
Upon released by activated PMNs, MPO transform the 
plaque into unstable form with large lipid core and thin 
fibrous cap. Soluble CD40 ligand released after plate-
let activation trigger an inflammatory response in vas-
cular endothelial cells by the secretion of cytokines and 
chemokines. In addition to inflammatory properties, 
sCD40L stabilizes platelet–platelet aggregates and initi-
ates further platelet activation during thrombosis after 
plaque rupture. PlGF stimulates vascular inflammation 
by promoting endothelial activation and macrophage 
recruitment into atherosclerotic lesions.
However, there is limitation in this study. We only man-
aged to obtain coronary blood sample from coronary ostium 
Table 4 Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in both CSA and ACS patients
CRP C-reactive protein, MPO myeloperoxidase, sCD40L soluble CD40 ligand, PlGF placental growth factor
Data were given as median (IQR)
* Significant with p < 0.05
a p: p value for the Wilcoxon signed-ranks test
b p: p value of the correlation test
CRP (mg/L) MPO (ng/mL) sCD40L (ng/mL) PlGF (pg/
mL)
CSA
 Coronary 3.14 (1.60–6.40) 442.88 (256.38–525.20) 1.90 (1.34–3.77) 51.57 (8.85–
81.66)
 Systemic 3.97 (2.39–8.38) 426.06 (351.28–511.93) 1.84 (0.90–3.15) 16.28 (6.63–
36.44)
 p valuea 0.001* 0.192 0.038* <0.001*
 Spearman’s ρ 0.904 0.427 0.433 0.663
 p valueb <0.001* 0.006* 0.005* <0.001*
ACS
 Coronary 16.34 (4.93–40.12) 608.75 (283.54–998.22) 3.19 (1.66–6.60) 53.43 (37.72–
74.69)
 Systemic 22.03 (4.72–45.86) 529.53 (323.91–1015.33) 2.95 (1.31–7.14) 42.36 (23.72–
59.54)
 p valuea 0.199 0.567 0.759 0.009*
 Spearman’s ρ 0.961 0.818 0.597 0.475
 p valueb <0.001* <0.001* <0.001* 0.002*
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in CSA patients since the use of export aspiration catheter is 
not a routine practice in percutaneous transluminal coro-
nary angioplasty (PTCA) procedure for CSA patients.
Conclusion
In summary, the systemic concentrations of CRP, MPO, 
sCD40L and PlGF were increased in ACS compared to 
CSA patients. This study used an advanced sampling tech-
nique to sample the blood from the primary site of the 
culprit lesion in coronary artery and the events happen-
ing at the primary site were compared with those in the 
systemic circulation by comparing the differences in bio-
markers at both sites. No significant difference was found 
between coronary and systemic values of CRP, MPO and 
sCD40L. The level of PlGF in the coronary circulation was 
significantly higher than its level in the systemic circula-
tion of ACS patients. Thus, this study hypothesized that the 
PlGF in the ACS patients could be released from ruptured 
coronary plaques or produced by the occluded coronary 
arteries. The coronary levels of the markers established 
significant correlations with those in systemic circulation. 
Hence, this study concluded that the concentrations of 
CRP, MPO, sCD40L and PlGF sampled in the systemic cir-
culation directly reflected those in the coronary circulation.
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